{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:33:45Z","timestamp":1777059225985,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.xphs.2016.06.014","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T16:57:18Z","timestamp":1471021038000},"page":"3046-3056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Accelerating Vaccine Formulation Development Using Design of Experiment Stability Studies"],"prefix":"10.1016","volume":"105","author":[{"given":"Patrick L.","family":"Ahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Pixley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Dieter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryann","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Przysiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Blue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.xphs.2016.06.014_bib1","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1056\/NEJMms1215400","article-title":"Contagious diseases in the United States from 1888 to the present","volume":"369","author":"van Panhuis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2016.06.014_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14760584.2014.907528","article-title":"Physicochemical and functional characterization of vaccine antigens and adjuvants","volume":"13","author":"Dey","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2016.06.014_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/026119290903701S05","article-title":"An immunologic model for rapid vaccine assessment\u2014a clinical trial in a test tube","volume":"37","author":"Higbee","year":"2009","journal-title":"Altern Lab Anim"},{"issue":"10","key":"10.1016\/j.xphs.2016.06.014_bib4","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1002\/jps.22618","article-title":"Multidimensional methods for the formulation of biopharmaceuticals and vaccines","volume":"100","author":"Maddux","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.014_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jps.23375","article-title":"Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine","volume":"102","author":"Hu","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.06.014_bib6","series-title":"Pharmaceutical Stress Testing: Predicting Drug Degradation","first-page":"426","article-title":"Stress testing to determine liposome degradation mechanisms","author":"Meers","year":"2011"},{"key":"10.1016\/j.xphs.2016.06.014_bib7","series-title":"DOE Simplified: Practical Tools for Effective Experimentation","first-page":"241","author":"Mark","year":"2007"},{"issue":"24","key":"10.1016\/j.xphs.2016.06.014_bib8","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.vaccine.2014.02.028","article-title":"Implementation of QbD for the development of a vaccine candidate","volume":"32","author":"Haas","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.014_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1586\/14760584.2014.874949","article-title":"Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine","volume":"13","author":"Esposito","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.014_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14760584.2015.1015997","article-title":"Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine","volume":"14","author":"Brendish","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.xphs.2016.06.014_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.014_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/IAI.67.1.113-119.1999","article-title":"Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice","volume":"67","author":"Saunders","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.xphs.2016.06.014_bib13","series-title":"Vaccine against Gram\u00a0Negative Bacteria","author":"Zollinger","year":"2003"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2016.06.014_bib14","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.xphs.2016.06.014_bib15","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1074\/jbc.C800214200","article-title":"Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis","volume":"284","author":"Cantini","year":"2009","journal-title":"J\u00a0Biol Chem"},{"issue":"31","key":"10.1016\/j.xphs.2016.06.014_bib16","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.xphs.2016.06.014_bib17","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto","year":"2011","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.xphs.2016.06.014_bib18","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A\u00a0phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA","volume":"28","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2016.06.014_bib19","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1016\/j.vaccine.2016.05.049","article-title":"Improving the immunogenicity of a novel trivalent Neisseria meningitidis outer membrane vesicle vaccine by genetic modification","volume":"34","author":"Zhang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2016.06.014_bib20","series-title":"Guidance for Industry. Q8 (R2) Pharmaceutical Development","author":"US Food and Drug Administration","year":"2009"},{"issue":"10","key":"10.1016\/j.xphs.2016.06.014_bib21","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s11095-014-1359-6","article-title":"Development of thermostable lyophilized inactivated polio vaccine","volume":"31","author":"Kraan","year":"2014","journal-title":"Pharm Res"},{"issue":"5-6","key":"10.1016\/j.xphs.2016.06.014_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.vaccine.2003.08.027","article-title":"Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines","volume":"22","author":"Arigita","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.014_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1208\/s12248-013-9485-3","article-title":"Non-Arrhenius protein aggregation","volume":"15","author":"Wang","year":"2013","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.014_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.014_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.014_bib26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/jps.22385","article-title":"Ultraviolet spectroscopy as a tool in therapeutic protein development","volume":"100","author":"Mach","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2016.06.014_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.xphs.2016.06.014_bib28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A\u00a0phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.xphs.2016.06.014_bib29","doi-asserted-by":"crossref","first-page":"17128","DOI":"10.1073\/pnas.1419686111","article-title":"Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody","volume":"111","author":"Malito","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.xphs.2016.06.014_bib30","doi-asserted-by":"crossref","first-page":"e1002981","DOI":"10.1371\/journal.ppat.1002981","article-title":"Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules","volume":"8","author":"Johnson","year":"2012","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.014_bib31","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/IAI.01183-13","article-title":"Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates","volume":"82","author":"van der Veen","year":"2014","journal-title":"Infect Immun"},{"issue":"Pt 5","key":"10.1016\/j.xphs.2016.06.014_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1107\/S1744309111006154","article-title":"Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086)","volume":"67","author":"Cendron","year":"2011","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"issue":"9","key":"10.1016\/j.xphs.2016.06.014_bib33","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1073\/pnas.1222845110","article-title":"Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen","volume":"110","author":"Malito","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916415121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916415121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T04:21:14Z","timestamp":1601007674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916415121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0022354916415121"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.06.014","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating Vaccine Formulation Development Using Design of Experiment Stability Studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}